The Academy of Managed Care Pharmacy is proud to announce the launch of the Biosimilars Resource Center, an unbiased, policy-neutral repository of educational resources and information on biosimilars for pharmacists, physicians, nurses and other health care providers.
Biosimilars show promise for treatment of treat autoimmune diseases and hematological cancers.
With the introduction of biosimilars in the United States, there are several significant issues that will challenge those involved in formulary committees and benefit plans, as well as prescribers and pharmacists.
To ensure patient access to newer, more affordable versions of biologic medicines, the Food and Drug Administration should avoid requiring a statement of biosimilarity on the product label, a group of leading pharmaceutical supply chain organizations stated in a letter submitted to the agency today
As new biosimilars enter the market, pharmacies should carefully consider infrastructure, resources, and strategies for successfully integrating the products into their portfolio of offerings.
Remicade treats rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, plaque psoriasis, and ulcerative colitis.
The FDA approved 700 generic drugs in 2015.
Several biologic drug manufacturers face biosimilar competition, but are financial markets pricing them appropriately?
The interests of payors, physicians, and patients must be addressed for biosimilars to offer cost savings.
Biosimilar infliximab-dyyb (Inflectra) treats a variety of autoimmune diseases.
Biosimilar infliximab-dyyb (Inflectra) treats a variety of autoimmune diseases, including Crohn’s disease, rheumatoid arthritis, and psoriatic arthritis.
Policy decisions will affect how much biosimilars improve patient access to advanced treatments.
Most read articles of the week on Specialty Pharmacy Times.
The Generic Pharmaceutical Association and its Biosimilars Council are pleased that the Food and Drug Administration (FDA) has issued its draft guidance on biosimilar labeling.
Access to biologics increased by as much as 100% after biosimilars became available.
Biosimilars face scrutiny before they can be indicated for inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis.
Although only 1 biosimilar has been approved in the United States thus far, pharmacists can expect to see a lot more action in this space in the next few years.
Controversy swirls around the naming protocol for biosimilars among drug manufacturers and the FDA.
There are several ongoing global phase 3 clinical trials for biosimilar adalimumab, which treats conditions such as rheumatoid arthritis, psoriatic arthritis, and Crohn's Disease.
A summary of the clinical potential of biosimilar therapies and special considerations for older patients with cancer.
The drug is the first biosimilar monoclonal antibody to be considered by the FDA.
Pharmacists must understand the potential value of biosimilars as a competitive generation of more cost efficient drugs hit the market.
National Association of Specialty Pharmacy (NASP) Executive Director James E. Smeeding, RPh, MBA, discusses the potential of biosimilars to reduce the cost burden of specialty pharmaceuticals.
Submission bolstered by trials evaluating biosimilar candidate in moderate-to-severe plaque psoriasis and rheumatoid arthritis.
